CollPlant, Israel-based maker of regenerative tissue, files for $25M IPO

CollPlant, an Israel-based biotech focused on regenerative medicine for tissue repair, is looking to raise $25 million in an initial public offering, according to an SEC filing.

CollPlant markets wound care and orthopedics scaffolds that are based upon its virgin collagen, Collage, which is derived from plants. It offers the first plant-derived source of Type I recombinant human collagen, according to the company.

In the regulatory filing, the company said it plans to list on the Nasdaq under the symbol “CLGN.” The sole bookrunner for the offering was listed as Ladenburg Thalmann & Co. No pricing terms were outlined in the filing.


Like this story? Subscribe to FierceBiotech!

Biopharma is a fast-growing world where big ideas come along every day. Our subscribers rely on FierceBiotech as their must-read source for the latest news, analysis and data in the world of biotech and pharma R&D. Sign up today to get biotech news and updates delivered to your inbox and read on the go.

“We believe the market opportunity for our current product candidates utilizing our rhCollagen platform technology exceeds $5 billion,” the company said.

Its VergenixSTR, which was granted at CE Mark last week, is an orthobiologic used to treat indications within the soft tissue repair market. According to CollPlant, more than 4.4 million procedures are carried out for the treatment of tendinopathy each year in the U.S. alone, which would give the company a target market for VergenixSTR of about 3 million procedures per year, or about a $2 billion market.

The company went public on the Tel Aviv Stock Exchange in 2010 through a reverse merger.


Suggested Articles

By employing heart rate signals, physical activity and sleep quality, common Fitbit trackers may be able to predict the spread of the flu.

Nanox has raised $26 million to help fuel the development and commercialization of its Star Trek-inspired digital X-ray bed.

Oncology is clearly a major medical and societal issue, but one that sees too much focus from biopharmas at the expense of other killers.